Among various surface molecules screened, CXCR4 was significantly up-regulated on monocytes, neutrophils, B cell subsets, and plasma cells in multiple murine models of lupus with active nephritis, including B6.Sle1Yaa, BXSB, and MRL.lpr. TLR-mediated signaling and inflammatory cytokines accounted in part for this increase. Increased CXCR4 expression was associated with functional consequences, including increased migration and enhanced B cell survival. Simultaneously, the ligand for CXCR4, CXCL12, was significantly up-regulated in the nephritic kidneys. Treatment with a peptide antagonist of CXCR4 prolonged survival and reduced serum autoantibodies, splenomegaly, intrarenal leukocyte trafficking, and end organ disease in a murine model of lupus. These findings underscore the pathogenic role of CXCR4/CXCL12 in lymphoproliferative lupus and lupus nephritis and highlight this axis as a promising therapeutic target in this disease.
I
n the immune system, CXCR4 (CD186) is a G protein-coupled receptor that serves many functions. Studies of mice carrying a targeted gene disruption of CXCR4 have revealed its critical role in hematopoiesis, B cell lymphopoiesis, myelopoiesis, germinal center organization, and maintenance of stem cell pools in the bone marrow (1) (2) (3) (4) (5) . Additionally, CXCR4 is a wellstudied molecule in both HIV and cancer. Of note, CXCR4 tropism was found to be correlative with chronic immune activation and AIDS pathogenesis (6, 7) , and studies in a variety of human cancers have shown the chemotaxis-inducing potential of CXCR4 to be exploited during tumor cell metastasis (8) . CXCR4 defects in humans lead to a syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis, collectively termed the WHIM syndrome (9) .
CXCR4 monogamously recognizes the CXCL12, also known as stromal cell-derived factor 1 (SDF-1), or pre-B cell growth-stimulating factor (PBSF). CXCL12 is known to be basally expressed by a variety of tissues, including skin, heart, and kidney (10) , and has been shown to be selectively up-regulated in a wide range of tissues in response to damage, particularly the kidney (11) . The up-regulation of CXCL12 has been postulated to promote mobilization and recruitment of CD34 ϩ progenitor cells to sites of damage as a mechanism of repair and repopulation. In the immune system, CXCL12 plays a major role in determining differential leukocyte output from the bone marrow. Low bone marrow levels of CXCL12 induced by inflammation promote granulocyte production and suppress B cell generation (12) . We initially became interested in CXCR4 because we observed that it was dysregulated in expression in the BXSB model of spontaneous murine lupus (our unpublished observation). Microarray screens of LPS-stimulated bone marrow-derived macrophages revealed that CXCR4 was highly up-regulated when compared with C57BL/6 (B6) controls. Given the known roles of CXCR4 in chemotaxis and B cell lymphopoiesis (4, 5) and the reported roles of CXCL12 in other forms of renal damage, we postulated that increased CXCR4 expression may play a role in mediating autoreactivity and nephritis in this disease. In this work, we examine the expression of CXCR4 and its ligand in different murine models of lupus, the mechanistic basis for this increase, and the therapeutic potential of blocking this axis in this disease.
Materials and Methods

Mice
Male B6, B6.Sle1, B6.Yaa, B6.Sle1Yaa, BXSB, and MRL.lpr mice and female B6.Sle1Sle2Sle3 mice were purchased from The Jackson Laboratory or bred in our colony at the University of Texas Southwestern Medical Center and housed in the University of Texas Southwestern Medical Center Animal Resources Center's specific pathogen-free facility. The care and use of laboratory animals in our facility conforms to the National Institutes of Health guidelines and Institutional Animal Care and Use Committeeapproved animal protocols.
Red, and 7-aminoactinomycin D (Invitrogen). Samples were Fc-blocked with the 2.4G2 Ab or 10% normal rabbit sera (Invitrogen). For spleen, bone marrow, and blood, at least 5 ϫ 10 4 cells were acquired in the live gate, as defined by size and granularity. For kidney samples, at least 5 ϫ 10 5 cells were acquired on the leukocyte gate, as defined by size and CD45 positivity. Samples were either acquired on an LSR II flow cytometer or FACSCalibur (BD Biosciences) and analyzed using FlowJo (Tree Star). MFIs represent mean fluorescent intensities. 3 
Isolation of renal leukocytes
Mice were perfused with 20 ml of cold PBS to remove the blood (Invitrogen). One-half of a kidney was harvested for histological analyses. The remainder was mechanically disrupted and incubated with 1 mg/ml collagenase IV (Sigma-Aldrich) and 1000 U/ml DNase (Roche) for 5 min in a 37°C water bath, and then at 37°C for 30 min with shaking. Cells were furthered mechanically disrupted by passage through a 23-gauge needle and then subjected to hypotonic shock with potassium acetate lysis buffer to remove residual RBC (Sigma-Aldrich). Cells were centrifuged at 3000 rpm at 25°C through a 40% Percoll (Sigma-Aldrich) gradient for 20 min. Leukocytes were recovered from the pellet and then enumerated by trypan blue exclusion and subjected to flow cytometric analysis.
In vitro splenocyte stimulation
Sterile splenocyte suspensions were plated in triplicate at 0.5 ϫ 10 6 cells/ml in complete medium (RPMI 1640 with L-glutamine, 10% FCS (HyClone), HEPES (Sigma-Aldrich), 1ϫ penicillin/streptomycin (SigmaAldrich), 2-ME (Sigma-Aldrich), L-glutamine (Sigma-Aldrich)) with varying concentrations of the following stimuli: recombinant CXCL12 (R&D Systems), with or without anti-IgM F(abЈ) 2 , and anti-CD40 (Jackson ImmunoResearch Laboratories). Cells were cultured at 37°C for 72 h and analyzed by flow cytometry.
In vitro macrophage stimulation
Bone marrow-derived macrophages were derived from 6-to 8-wk-old B6 males, as described (31). Macrophages were plated at 5 ϫ 10 5 cells/ml and stimulated for 24 h with TNF-␣ (0.05 ng/ml), IL-1-␤ (10 pg/ml), and/or IL-6 (0.1 ng/ml) (all from R&D Systems). For the blocking studies, macrophages were stimulated with 10 ng/ml LPS (Sigma-Aldrich) and treated with anti-TNF-␣ (0.5 g/ml), anti-IL-1␤ (5 g/ml), and/or anti-IL-6 (0.5 g/ml) (all from R&D Systems). For flow cytometry analyses, at least 3 ϫ 10 4 cells were acquired in the macrophage gate (i.e., cells that were CD11b ϩ F4/80 ϩ ) and examined for CXCR4 expression.
Transwell migration
Transwell plates (6.5 mm) with 5.0-m-pore polycarbonate membranes (Corning) were used. Six hundred microliters of 50 ng/ml CXCL12 was placed in the lower chamber and preincubated at 37°C for 2 h to equilibrate the membrane. Splenocytes (1.5 ϫ 10 6 ) were loaded into the upper well of the transwell plate. In some experiments, cells were resuspended in complete RPMI 1640 medium containing various doses of the CXCR4 inhibitor CTCE-9908 (Chemokine Therapeutics). Cells were allowed to migrate for 2 h at 37°C. Cells in the lower chamber were counted using trypan blue exclusion and analyzed by flow cytometry.
Renal cell supernatant and ELISA
Mice were perfused with 20 ml of PBS, and single-cell suspensions of the kidney were prepared by mechanical disruption and collagenase digestion. Cell suspensions (500 l of PBS per two kidneys) were centrifuged at 1,500 rpm for 7 min, and the supernatant was collected and further centrifuged at 14,000 rpm for 10 min. Supernatant (termed "renal plasma") was collected and used at various dilutions to quantitate CXCL12 concentration by ELISA (R&D Systems). OD 450 was measured by an Elx800 automated microplate reader (BioTek Instruments) and concentrations were extrapolated from a 4-point standard curve (R 2 Ͼ 0.99), where the mean of experimental duplicates was used.
Immunohistochemistry
Paraffin sections (5 m) of the kidney were boiled in 10 mM citrate, quenched with 0.01% NaBH 4 , blocked with murine F(abЈ) 2 anti-IgG (Jackson ImmunoResearch Laboratories), and stained with anti-mouse SDF-1/ CXCL12 Ab (R&D Systems) at 4°C overnight. Sections were then washed and incubated with goat anti-mouse IgG conjugated to Cy3 (Jackson ImmunoResearch Laboratories) for 1 h at room temperature. Sections were washed and then mounted with Vectashield (Vector Laboratories), visualized, and photographed with a Zeiss Axioplan 2 digital camera and analyzed using AxioVision (Zeiss).
In vivo inhibition of CXCR4
The peptide antagonist CTCE-9908 (Chemokine Therapeutics) was resuspended in 5% dextrose water. Two cohorts of B6.Sle1Yaa male mice were assembled for the in vivo "prevention" or "treatment" studies. In cohort I, comprised of 2-mo-old mice, 5 were injected with vehicle and 11 received CTCE-9908. In cohort II, comprised of antinuclear autoantibody (ANA) FIGURE 1. Increased CXCR4 expression in murine models of lupus. Splenic (A) and peripheral blood (B) leukocytes from 9-to 12-mo-old male B6.Sle1Yaa, BXSB, MRL.lpr, and B6 mice (n ϭ 6 -10 each) were subjected to flow cytometric analyses. Table I . Shown in C are representative histogram overlays of CXCR4 staining.
-seropositive 4-mo-old mice, 5 were injected with vehicle and 8 were injected with CTCE-9908. In both study groups, 100 l of CTCE-9908 at 50 mg/kg or vehicle placebo were injected i.p. three times a week for the course of study (i.e., until 6 mo of age or until death). All mice were monitored for serum autoantibodies, proteinuria, azotemia, and evidence of renal pathology, as detailed below.
Serology
Mice were bled before and at 1, 2, 3, and 4 mo after treatment with CTCE-9908 or placebo and the sera were stored at Ϫ20°C. ELISA detection of serum IgM and IgG autoantibodies to chromatin and dsDNA were performed as described (13) . OD 450 was measured using an Elx800 automated microplate reader (Bio-Tek Instruments), and the raw optical densities for anti-chromatin Abs were converted to arbitrary normalized units using a 6-point standard curve generated by an antinuclear mAb derived from a NZM2410 mouse (13) .
Assessment of renal disease
Twenty-four hour urine samples were collected using metabolic cages for proteinuria analyses, which were assessed using the Coomassie Plus protein assay kit (Pierce) with BSA as a standard. OD 630 was measured using an Elx800 automated microplate reader (Bio-Tek Instruments). Blood urea nitrogen was assessed using the QuantiChrom urea assay kit (BioAssay Systems). The extent of glomerular and tubulointerstitial disease and the percentage of glomerular crescent formation were scored as detailed elsewhere (14) .
Statistical analysis
For the in vivo disease prevention/treatment studies, the experimental mice were compared with the placebo group wherever sufficient placebo mice were still alive. For the 6 mo of age comparisons, since most of the placebo controls were already dead, 5-to 6-mo-old untreated B6.Sle1Yaa mice were used as controls for the statistical analyses. Data were analyzed using InStat3 or GraphPad 4 (GraphPad Software). Where appropriate, one-way ANOVA with Dunnett or Bonferroni post hoc analysis, Welch t test, Mann-Whitney U test, or log rank (Mantel-Cox) test were used. Error bars represent SEMs.
Results
Increased CXCR4 expression on leukocytes of multiple murine lupus strains is a consequence of disease
Examination of several murine lupus models, including BXSB, MRL.lpr, and B6.Sle1Yaa, revealed that CXCR4 was significantly up-regulated on multiple cell types in 8-to 10-mo-old mice, regardless of their genetic composition, when compared with B6 controls ( Fig. 1 and Table I ). Similar differences were noted in a fourth lupus-prone strain, B6.Sle1Sle2Sle3 (Table I) . Cell types that exhibited the largest up-regulation of CXCR4 compared with B6 in all murine models included cell subsets of both the myeloid and B cell lineages. In particular, inflammatory monocytes, neutrophils, plasma cells, and pre-plasma cells expressed the highest absolute levels of CXCR4, particularly in the lupus-prone strains ( Fig. 1 and Table I ). Both in terms of the MFIs, as well as the percentage of cells expressing CXCR4, myeloid and B cells from lupus mice exhibited an ϳ2-fold increase in surface expression of CXCR4. Although these differences were most marked on splenic leukocytes, a similar pattern of expression difference was also noted on leukocytes isolated from lymph nodes, peripheral blood, and the bone marrow (Table I and data not shown). Although we detected an increase in CXCR4 expression on memory CD4
ϩ T cells, these results did not reach statistical significance.
CXCR4 is located on murine chromosome 1 at 130 Mb, centromeric to the Sle1 interval (with Sle1b being located at 174 Mb). To examine if CXCR4 hyperexpression was due to a genetic polymorphism or whether it arose as a consequence of disease, we adopted two approaches, using the B6.Sle1Yaa strain as a disease model. First, evaluation of young (2-mo-old) predisease B6.Sle1Yaa mice did not reveal a similar degree of CXCR4 hyperexpression compared with young B6 controls FIGURE 2. CXCR4 hyperexpression in B6.Sle1Yaa mice is not the direct consequence of either locus, but arises as a result of the disease. A, Comparison of mean percentage of CXCR4 ϩ cells on young (age Յ2 mo) B6.Sle1Yaa mice compared with age-matched B6 mice (n ϭ 15). B and C, Mean percentages of myeloid cells or plasma cells that express CXCR4 in 9-mo-old B6.Sle1Yaa mice or the related age-matched monocongenic strains (n ϭ 6 each) in the blood and spleen, respectively. ANOVA with Dunnett posthoc test was used for statistical analyses: ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001. ( Fig. 2A) . Second, we examined monocongenic mice bearing the two main genetic elements that dictate lupus development in B6.Sle1Yaa mice: Sle1 z and Yaa (15) (16) (17) (18) . Interestingly, the upregulation of CXCR4 was present only in the bicongenic mice, and only in mice with active lupus, defined by the presence of IgG ANA (antichromatin) seropositivity and active proteinuria Ͼ1 mg/24 h (Fig. 2) . In contrast, the up-regulation of CXCR4 was not observed in B6.Sle1 or in B6.Yaa mice (Fig. 2) . Furthermore, direct sequencing of the CXCR4 gene revealed no sequence polymorphisms between B6 and B6.Sle1Yaa (data not shown). Taken together, these data indicate that the up-regulation of CXCR4 on B6.Sle1Yaa leukocytes is unlikely to be the direct consequence of any single genetic contribution responsible for disease (i.e., Sle1 or Yaa), but is instead likely to be the downstream consequence of the disease process.
TLR stimulation and inflammatory cytokines may be responsible for the increased CXCR4 expression in murine lupus
We next explored the mechanistic basis of CXCR4 up-regulation in lupus. B cell receptor ligation with or without CD40L ligation or PMA was not able to up-regulate CXCR4 on B cells; likewise, stimulation of T cells in vitro with anti-CD3, anti-CD28, PMA, or Con A were also not able to up-regulate CXCR4 (data not shown). In contrast, TLR ligation and inflammatory cytokines appeared to be potent at up-regulating CXCR4 expression in vitro (Fig. 3A) . This was partly dependent on inflammatory cytokine production since LPS-induced CXCR4 up-regulation was partly dampened by Abs to IL-1␤, Il-6, and TNF-␣ (Fig. 3A) . Interestingly, in all conditions in which IL-6 was neutralized, we observed a significant decrease in CXCR4 expression compared with LPS-treated macrophages, although both direct signaling through TLR4 as well as synergistic effects of both IL-1-␤ and TNF-␣ seem to also play a role in mediating CXCR4 up-regulation. Likewise, when we stimulated macrophages directly with these recombinant cytokines, all conditions in which IL-6 was added led to significantly increased CXCR4 expression compared with unstimulated macrophages (Fig. 3B ). These observations are likely to be physiologically relevant since these cytokines were elevated in murine lupus, including the B6.Sle1Yaa strain (Fig. 3, C-E) that shows prominent CXCR4 up-regulation on various leukocyte subsets. Collectively, these studies indicate that TLR ligation and inflammatory cytokines (rather than Ag receptor stimulation) may be playing key roles in orchestrating the CXCR4 increase seen in lupus. On the other hand, neither stimulation of ϩ leukocytes in lupus kidneys. Whole kidneys from the indicated strains (at 9 -12 mo of age) were subjected to digestion and Percoll density centrifugation, as detailed in Materials and Methods. The fraction enriched for leukocytes was enumerated using trypan blue exclusion and subjected to flow cytometric analyses. A, Cellular constituents of the leukocyte-enriched preparations. The SSC/CD45-defined gate depicted in the top row was used to identify leukocytes, which were then characterized using additional surface markers, as shown in the second and third rows. cells with the TLR7 agonist R837, the cytokine IFN-␣, or a variety of TLR9 agonistic CpG oligodeoxynucleotides were able to up-regulate CXCR4 (data not shown).
Increased CXCR4 expression leads to increased migration to positive CXCL12 gradients and increased B cell survival
We next examined the functional consequences of up-regulation of CXCR4 in diseased mice. Three-fold more B6.Sle1Yaa splenocytes, which express more CXCR4, migrated to positive CXCL12 gradients when compared with B6 controls (Fig. 4A) . Among the cell types that expressed CXCR4, the migratory potential of neutrophils, monocytes, and B cells differed most significantly between the strains, although all cell types from diseased mice that express higher CXCR4 levels migrated better to CXCL12 compared with the B6 controls (Fig. 4 and data  not shown) . Also, when CXCL12 was added to both the top and bottom chambers, no significant migration was observed (data not plotted), excluding chemokinesis as a possible explanation for these data.
In addition to its role in chemotaxis, CXCL12 has also been shown to impact B cell lymphopoiesis (19) . Therefore, we assessed whether increased CXCR4 expression affected the responses of B cells to stimulation with CXCL12. We found that BCR-ligated B cells from B6.Sle1Yaa spleens showed significantly better survival when exposed to CXCL12 (Fig. 4B) . We detected no differential B cell responses to CXCL12 in terms of proliferation or the expression of activation markers assessed (data not shown). We also detected no difference in the proliferation or activation of B6.Sle1Yaa T cells when exposed to CXCL12 (data not shown). These data indicate that the increased expression of CXCR4 on lupus leukocytes is associated with multiple functional consequences, the most profound of which include enhanced BCRtriggered B cell survival and chemotaxis to positive CXCL12 gradients.
FIGURE 7.
Early administration of a CXCR4 peptide antagonist prevents lupus. Two-month-old B6. Sle1Yaa males (cohort I) were injected with CTCE-9908 (n ϭ 11) or vehicle placebo (n ϭ 5). All mice were sacrificed at the age of 5-6 mo. One hundred microliters of CTCE-9908 at 50 mg/kg or vehicle placebo was injected i.p. three times a week for the course of study (i.e., from the age of 2 mo until 5-6 mo of age or until spontaneous death). A, Survival curve for mice in the prevention study (cohort I). B, Spleen sizes upon sacrifice of the mice; examples of spleens from the respective strains are presented as insets. C, Antichromatin ANA levels (as assayed by ELISA) over the course of the treatment regime. D, Total proteinuria levels detected in 24 h urine collections at the indicated ages. E, Histopathological findings upon sacrifice at 6 mo. CTCE-9908 and Placebo refer to B6.Sle1Yaa mice that received experimental or placebo treatment, respectively, while B6 and B6.Sle1Yaa refer to unmanipulated controls (n ϭ 5 each). Top, Representative histological images: 1, B6 control; 2, B6.Sle1Yaa; 3, CTCE-9908 treated; 4, placebo-treated. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001 by log rank (Mantel-Cox) test, Welch-corrected t test, or the Mann-Whitney U test, where appropriate. Note that for all studies executed at the terminal 6-mo age point (B-E), untreated 5-to 6-moold B6.Sle1.Yaa mice were used as the control group because insufficient placebo-treated mice survived to 6 mo of age (as can be surmised from A).
Increased renal expression of CXCL12 in lymphoproliferative lupus
We next examined if the increased renal disease in lupus might be in part driven by heightened CXCR4/CXCL12 activity. We observed a robust increase in CXCL12 expression in the kidneys of B6.Sle1Yaa, but not B6, mice both by immunohistochemistry (Fig.  5A ) and by ELISA (Fig. 5B) . We observed increased CXCL12 expression in both the glomeruli and the tubules. More CXCL12 was also expressed in the interstitium, as well as in the Bowman's capsules of B6.Sle1Yaa kidneys, compared with B6 controls (Fig.  5A) . Similar increases were also observed in BXSB and MRL.lpr kidneys (data not shown). In addition to the increase in CXCL12, we also noted CXCR4 ϩ cells to accumulate within B6.Sle1Yaa kidneys when examined ex vivo (Fig. 6) . Collectively, these data suggest that the CXCR4/CXCL12 axis may be instrumental for leukocyte trafficking into the kidneys, and thus it may play an important role in mediating renal pathology in lupus nephritis.
Pharmacological inhibition of CXCR4 significantly ameliorates disease
To explore if increased CXCR4/CXCL12 might be a good therapeutic target in lupus, we tested the CXCR4 peptide antagonist CTCE-9908. Initial characterization indicated that CTCE-9908 was effective in blocking chemotaxis by B6.Sle1Yaa splenocytes in vitro, with the migration of all cell types being inhibited equally (supplemental Fig. S1 ). 4 To test the therapeutic efficacy in vivo, B6.Sle1Yaa mice were subjected to two sets of placebo control studies. First, the preventive efficacy of CXCR4 blockade was tested on a cohort of 2-mo-old B6.Sle1Yaa mice (cohort I), which typically do not have antinuclear Abs or nephritis. Second, the therapeutic efficacy of CXCR4 blockade was tested on 4-mo-old B6.Sle1Yaa mice (cohort II), which by this age have already developed detectable impairment of renal function, high titers of ANAs, and a large spectrum of immunological changes (18) .
Blocking the CXCR4 axis from the age of 2 mo significantly prolonged survival (by about 2 mo) and reduced splenomegaly ( p Ͻ 0.05), T cell and B cell activation ( p Ͻ 0.05), autoantibody production ( p Ͻ 0.001), and nephritis ( p Ͻ 0.01) (Fig. 7 and Table  II ). In particular, tubulointerstitial disease and crescent formation, rather than glomerulonephritis, were the pathological features that were most significantly reduced ( p Ͻ 0.01; Fig. 7 ). The observed change in splenomegaly was accompanied by significant reductions in peripheral T and B cells, as well as various myeloid cells (cohort I in Table II) . Importantly, similar disease amelioration and lifespan prolongation was also seen when treatment was started after disease onset (Fig. 8 and data not shown) . Although splenic cellularity was not reversed in the latter study (cohort II in Table  II and data not shown), the treatment regimen significantly reduced renal disease, including tubulointerstitial disease ( p Ͻ 0.01), glomerulonephritis ( p Ͻ 0.001), and glomerular crescent formation ( p Ͻ 0.05) (Fig. 8) . The absolute numbers of leukocytes recruited into the kidneys, particularly various myeloid cell subsets, were significantly reduced by CXCR4 blockade, both in the prevention ( p Ͻ 0.001) and treatment ( p Ͻ 0.01) studies (Table II and Fig. 9 ). Both the preventation and therapeutic treatments were not associated with any changes in body weight, peripheral RBC counts, hemoglobin levels, or liver function tests (data not shown), alluding to the safety of the administered drug.
Discussion
The data presented in this communication suggest an important role for CXCR4/CXCL12 in mediating lymphoproliferative lupus and lupus nephritis. It is clear that CXCR4 is hyperexpressed in all mouse models of lupus examined in this study. These are genetically diverse, including strains harboring lupus susceptibility loci originating from the New Zealand Black/New Zealand White, BXSB, as well as the MRL.lpr genetic backgrounds. This observation suggests that CXCR4 hyperexpression may be a generalized feature of lupus, independent of the underlying genetic basis. In all of the strains examined, the highest levels of CXCR4 were noted on myeloid cells (particularly on neutrophils and inflammatory macrophages) as well as terminally differentiated B cells (notably on plasma cells and pre-plasmablasts), an observation that is consistent with the expression patterns reported in the literature (2-4, 4 The online version of this article contains supplemental material. ϩ T cells isolated from mice with lupus, these results did not reach statistical significance; this trend, however, is consistent with our previous studies using microarray analysis of splenic CD4 ϩ T cells, which revealed significantly increased CXCR4 mRNA in B6.Sle1Yaa, compared with B6, mice (18) .
Given the increased expression of CXCR4 on myeloid cells and terminally differentiated B cells, it appears most likely that altered trafficking patterns of these two cell types may be contributing to disease in lupus. With respect to the myeloid cells, the enhanced trafficking of these cells to the kidneys may be a key contributor to the heightened nephritis seen in these mice. This notion is supported by the observation that kidneys from lupus-afflicted mice exhibit profound increases in the absolute numbers of CXCR4 ϩ myeloid cell infiltrates, as well as the ligand for CXCR4, CXCL12 (Figs. 5 and 6 ). This was bolstered by the finding that blocking CXCR4 reverses the infiltration of myeloid cells into the kidneys and accompanying renal inflammation (Figs. 7-9 and Table II) . Among the myeloid cell subtypes that are most likely responsible for the renal pathology in these disease models are neutrophils and inflammatory monocytes, based on their highest CXCR4 expression levels and on previous literature reports (20 -21) . Indeed, the role of intrarenal CXCL12 in recruiting inflammatory cells into the kidneys has been elegantly demonstrated in other experimental models of nephritis (11, 20) .
The potential mechanisms through which CXCR4 ϩ B cells may be contributing to lupus are less obvious. Besides the enhanced chemotaxis toward CXCL12 (Fig. 4A) , the heightened CXCR4 levels on B cells is also likely to confer prolonged survival advantage to these presumably autoreactive B cells (Fig. 4B) . One can envision a scenario in which this could contribute to a breach in peripheral B cell tolerance. The prolonged survival of autoreactive germinal center B cells and plasma cells as a consequence of increased CXCL12-triggered signaling could potentially lead to increased autoantibody levels (21) (22) (23) . This model is consistent with the observation that blocking CXCR4/CXCL12 reduces autoantibody levels, particularly in the prevention study. Potentially, the increased CXCR4 levels on plasmablasts may facilitate increased trafficking of these cells to the kidneys and promote their survival within intrarenal niches; however, we did not find any increase in CXCR4 ϩ plasma cells (or B cells) within B6.Sle1Yaa kidneys (data not shown). Whether the CXCR4 ϩ plasma cells in lupus might have homed to yet other (i.e., nonrenal) niches is a question that warrants further study. Finally, since CXCR4 levels are tightly regulated in different subsets of germinal center B cells (3, 5) , a further possibility is that the heightened CXCR4 levels observed on lupus B cells may lead to altered trafficking and affinity maturation patterns within the germinal centers, a possibility that needs to be formally evaluated.
Given the observation that the heightened expression of CXCR4 on myeloid and B cells may have biological consequences that facilitate disease pathogenesis, a key question that arises is the potential therapeutic utility of CXCR4 blockade in lupus. Indeed, there has been an isolated report on the therapeutic benefit of targeting its ligand, CXCL12. Balabanian et al. showed that treatment of New Zealand Black/New Zealand White mice with anti-CXCL12 Ab ameliorated several lupus phenotypes, although in their study, the analyses were focused on the role of peritoneal B1a cells (24) . Given that CXCR4 also plays an important role in AIDS and tumor metastases, there has been a flurry of research reports based on novel CXCR4 blocking agents (25) (26) (27) (28) . This includes CTCE-9908 from Chemokine Therapeutics, which has proven effective in separate studies in osteosarcoma and prostate cancer (29, 30) . Preliminary phase I/II data supporting the inhibitory potential of this agent in solid tumors was recently presented at the American Association for Cancer Research-National Cancer InstituteEuropean Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) Molecular Targets and Cancer Therapeutics International Conference in October 2007 (29) . Given the demonstrated safety and reported efficacy of this agent in the completed and ongoing human clinical trials, this appeared to be a suitable drug choice for testing in lupus. Indeed, the early administration of the peptide antagonist of CXCR4 prevented all serological, cellular, and clinical manifestations of lupus, indicating that all component lupus phenotypes (and the associated pathogenic events) are absolutely dependent upon CXCR4 expression FIGURE 8. CXCR4 peptide antagonist decreases the severity of lupus nephritis even when administered after disease onset. Four-month-old ANA-seropositive B6.Sle1Yaa males (cohort II) were injected with CTCE-9908 (n ϭ 8) or vehicle placebo (n ϭ 5). One hundred microliters of CTCE-9908 at 50 mg/kg or vehicle placebo was injected i.p. three times a week for the course of study (i.e., from the age of 4 -6 mo or until spontaneous death). A, Survival curve for mice in the treatment study (cohort II). B, Total proteinuria levels detected in 24-h urine collections at the indicated ages. C, Glomerulonephritis scores, tubulointerstitial disease scores, and extent of glomerular crescent formation in kidneys obtained from the different groups of mice studied, upon sacrifice at 6 mo. CTCE-9908 and Placebo refer to B6.Sle1Yaa mice that received experimental or placebo treatment, respectively, while B6 and B6.Sle1Yaa refer to unmanipulated controls (n ϭ 5 each). Right, Representative histological images: 1, B6 control; 2, B6.Sle1Yaa; 3, CTCE-9908 treated; 4, placebo treated. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001 by log rank (Mantel-Cox) test, Welch-corrected t test, or the Mann-Whitney U test, where appropriate. Note that for all studies executed at the terminal 6-mo age point (B and C), untreated 5-to 6-mo-old B6.Sle1.Yaa mice were used as the control group because insufficient placebo-treated mice survived to 6 mo of age (as can be surmised from A).
early in the disease process. This might relate to the critical requirement for CXCR4 hyperexpression on B cells and myeloid cells to initiate autoantibody production and renal disease.
In contrast, when CXCR4 blockade is instituted late in disease, well after the onset of proteinuria and elevated serum autoantibodies, most of the cellular changes associated with lupus in the B6.Sle1Yaa model were recalcitrant to treatment. However, latephase therapy was still able to curtail the progression of renal disease, with attendant prolongation of lifespan in these mice. These observations have important ramifications. First, they suggest that the dominant cause of death in these mice is nephritis, rather than splenomegaly (or associated hematological abnormalities). Second, they indicate that renal disease in lupus can be divorced from systemic cellular and serological changes; in other words, mice with severe splenomegaly and high autoantibody levels can live a "normal" lifespan if the renal disease is therapeutically controlled. Third, in both the prevention and treatment studies, CXCR4 blockade dampened tubulointerstitial disease and crescent formation (rather than glomerulonephritis), two histopathological phenotypes associated with poor prognosis in lupus nephritis. Finally, these studies raise hope that instituting CXCR4 blockade in patients with active lupus nephritis might also be therapeutically effective. FIGURE 9. CXCR4 blockade reduces renal leukocyte infiltration in murine lupus nephritis. Two cohorts of B6.Sle1Yaa male mice were subjected to prevention or treatment studies using the CXCR4 peptide antagonist, CTCE-9908, as detailed above in Figs. 7 and 8 . A, Absolute numbers of CD45 ϩ cells in the kidneys of the indicated mice upon sacrifice at 6 mo; indicated below are representative two-dimensional plots demonstrating reduced percentage of leukocytes in the renal cell preparation. B, Gr-1/CD11b staining profiles of myeloid cell subsets within the kidneys in the different groups of mice upon sacrifice at 6 mo, and the absolute numbers of various myeloid cell subsets in the kidneys of mice from the different study groups, as further detailed in Table II 
